China Set to Become OxyContin’s Second Largest Market
China is set to become the second largest market for Mundipharma’s OxyContin behind the US. It comes as…
China
China Healthcare in 2019: Sprinting a Marathon
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look at China's skyrocketing health industry and what to expect from it in the…
China: A New Biopharma Model Emerging
Professor Richard Barker, founder of New Medicine Partners reflects on China’s very different approach to…
US-China Tensions Heating Up in the Life Sciences
Eurasia Group’s Aditya Bhattacharji looks at the potentially damaging fallout of the ongoing US-China trade war…
People To Know
Yifang Wu
CEO, President | Fosun Pharma
Xing Tian Ma
Chairman | Kangmei Pharmaceutical
Zheng Jianxiong
President, Director | Guangzhou Pharmaceutical Holdings
Zhou Yun Shu
CEO | Jiangsu Hengrui Medicine
Yuwen Gao
Chairman | China Meheco Group
In Conversation
Dafang Zhong – Director, Shanghai Center for Drug Metabolism and Pharmacokinetics Research, SIMM, CAS, China
Dr Dafang Zhong, director of Shanghai Center for Drug Metabolism and Pharmacokinetics Research at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, shares his professional career within the DMPK space, as well as the important work that the Center has done in contributing to the growth and development of the nascent Chinese innovative pharmaceutical industry, having worked on…
China Pharma Forecast 2019-2023
China has expanded to be the second largest pharmaceutical market globally with USD 137 billion in total spending…
Related Report
Regulatory Reform: China
The key facts about regulatory reforms in Chinese pharma. Prepared in association with Fangda Partners, one of…
4+7: China’s New Volume-Based Purchasing Policy
In late 2018 China adopted a novel procurement scheme with the aim of dramatically cutting the amount being paid…
First Ever Biosimilar Approval in China: Trouble for Roche?
China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be…
The Ideal Pharma Country Manager: China (Egon Zehnder)
Lydia Guo, Grace Zhao and Mendy Zhang of executive search firm Egon Zehnder outline some of the latest trends…
Chengdu: The First Steps Towards Mutual Insurance In China
Better known for its panda sanctuary and spicy local cuisine, Chengdu could be the first Chinese city to offer…
‘Made in China’ – a Badge of Dishonour?
One of China’s biggest vaccine manufacturers was found to have falsified rabies vaccine records causing…
China to Cut Taxes for Rare Disease Drugs
It has been announced by China’s State Council that as of March 1st 2019, the government will reduce the VAT…
dMed: More Than Just a CRO
Amidst the sea of Big Pharma executives jumping ship to start highly regarded and attention-grabbing biotech…
China to Establish National Medical Ethics Committee Post-CRISPR Controversy
China is planning to establish a new national medical ethics committee in the wake of the “CRISPR babies”…
The Ideal Pharma Country Manager: China (Cornerstone International)
What do executive recruitment firms look for when hiring country managers for multinational pharma companies in…
China’s Vaccine Crisis
One of China’s biggest vaccine manufacturers was found to have falsified rabies vaccine records causing…
China: Increased Regulation Leads to Flu Vaccine Shortages
Following China’s vaccine scandal earlier this year, the country’s drug administration has considerably…
Venture Capital and China’s Life Sciences: New Territories
Cash has always ruled the start-up world and when it comes to the healthcare and life sciences sphere, the heavy…
Chinese PD-1 Cancer Drugs: Global Competition for Big Pharma
PD-1 inhibitors have boosted survival rates for many cancer patients since their introduction in the US five years…
Bio 2019 / Hong Kong Biotech IPOs Soaring in Line with China Pharma Market
With Hong Kong now established as the world’s second largest funding hub for biotech, at this week’s BIO 2019…
Shanghai: At the Heart of Pfizer Upjohn’s Global Fight Against NCDs
On May 30th, and with much fanfare, Pfizer Upjohn officially inaugurated its global headquarters in the heart of…
Economic cooperation between Taiwan and China giving a boost to the Taiwanese…
Signed in June 2010, the Economic Cooperation Framework Agreement (ECFA) between Taiwan and China was set to reduce…
Chinese Government Outlines Healthcare Reform Priorities
More accessible and affordable healthcare for all: China’s government has outlined several proposals to…
China: Prescription Drugs Available Online via Loophole
Chinese ecommerce behemoths Alibaba and JD.com are being used to buy and sell tens of thousands of prescription…
China’s Belt and Road Initiative: Awakening the Dragon
China’s stupendous economic resurgence over the past four decades never ceases to awe, but what has captured…
China: Driving Big Pharma’s Sales Growth for the Long Term?
China is a hot topic in Big Pharma investor updates these days. The world’s second-largest pharmaceutical market…
The Ideal Pharma Country Manager: China (Ardent Search)
The lowdown on what it takes to be a country manager of a multinational pharma company in some of the world’s…
Hong Kong Now the World’s Second Largest Funding Hub for Biotech
Hong Kong is now the world’s second largest funding hub for biotech according to Hong Kong Chief Executive…
Pharma CEO Pair Become China’s Richest Couple
Following Hansoh’s recent IPO in Hong Kong, CEO Zhong Huijuan and husband Sun Piaoyang, CEO of Jiangsu…
China’s Greater Bay Area: Spearheading Innovation
Guangdong province and neighbouring Hong Kong have long been fundamental to China’s metamorphosis into an…
China’s Greater Bay Area and Hong Kong Life Sciences
One of the more eye-catching and ambitious initiatives to come out of last March’s National People’s Congress,…
Chinese Biotechs Paying Top Dollar for US and UK Drug Candidates
China’s rapidly-growing biotech sector is increasingly hungry for preclinical drug candidates to…
Orphan Drug Accessibility & Social Medical Coverage in China
Kevin Rufang Huang is the president and founder of the Chinese Organization for Rare Disorders (CORD). A rare…